
  
    
      
        Introduction_NNP
        More_JJR than_IN 35_CD million_CD HIV-infected_NNP people_NNS live_JJ in_IN developing_VBG countries_NNS with_IN significant_JJ
        resource_NN limitations_NNS ._. Although_IN 6_CD million_CD people_NNS living_VBG in_IN developing_VBG countries_NNS are_VBP in_IN
        urgent_JJ need_NN of_IN antiretroviral_NN therapy_NN ,_, only_RB 700_CD ,_, 000_CD currently_RB receive_VB effective_JJ treatment_NN
        [_NN 1_CD ]_NN ._. Global_JJ treatment_NN efforts_NNS ,_, including_VBG the_DT World_NNP Health_NNP Organization_NNP 's_POS
        â_NN €_NN œ_NN 3_CD by_IN 5_CD â_NN €_NN Initiative_NNP ,_, aim_NN to_TO extend_VB therapy_NN to_TO several_JJ million_CD
        people_NNS over_IN the_DT next_JJ few_JJ years_NNS [_NN 2_CD ]_NN ._. While_IN the_DT cost_NN of_IN antiretroviral_NN medications_NNS has_VBZ
        dropped_VBN considerably_RB ,_, other_JJ obstacles_NNS ,_, including_VBG the_DT cost_NN ,_, technical_JJ ,_, and_CC operational_JJ
        requirements_NNS of_IN CD_NNP 4_CD counts_VBZ ,_, viral_JJ loads_NNS ,_, and_CC other_JJ sophisticated_JJ diagnostic_JJ tests_NNS used_VBN to_TO
        initiate_VB and_CC monitor_VB HIV_NNP treatment_NN ,_, remain_VB to_TO be_VB addressed_VBN ._.
        In_IN particular_JJ ,_, measurements_NNS of_IN CD_NNP 4_CD
        +_NN T_NN lymphocytes_NNS are_VBP essential_JJ for_IN staging_NN HIV-infected_NNP patients_NNS ,_,
        determining_VBG their_PRP$ need_NN for_IN antiretroviral_NN medications_NNS ,_, and_CC monitoring_VBG the_DT course_NN of_IN their_PRP$
        infection_NN [_NN 3_CD ]_NN ._. The_DT CD_NNP 4_CD countâ_NN €_NN” expressed_VBD in_IN adults_NNS as_IN the_DT absolute_JJ number_NN
        of_IN CD_NNP 4_CD cells_NNS per_IN microliter_NN of_IN blood_NN ,_, and_CC in_IN children_NNS as_IN a_DT percentage_NN of_IN total_JJ lymphocytes_NNS
        or_CC total_JJ T_NN lymphocytesâ_NN €_NN” has_VBZ enormous_JJ prognostic_JJ and_CC therapeutic_JJ
        implications_NNS ,_, and_CC forms_VBZ the_DT basis_NN for_IN most_JJS HIV_NNP treatment_NN decisions_NNS
        [_NN 4_CD â_NN €_NN“ 6_CD ]_NN ._. In_IN developed_VBN countries_NNS ,_, CD_NNP 4_CD counts_NNS are_VBP typically_RB performed_VBN every_DT
        three_CD to_TO six_CD months_NNS for_IN each_DT patient_NN using_VBG the_DT method_NN of_IN flow_NN cytometry_NN ._. Flow_NNP cytometers_NNS
        use_VBP lasers_NNS to_TO excite_VB fluorescent_NN antibody_NN probes_NNS specific_JJ for_IN CD_NNP 4_CD and_CC other_JJ cell_NN surface_NN
        markers_NNS ,_, to_TO distinguish_VB one_CD type_NN of_IN lymphocyte_NN from_IN another_DT ._. Several_JJ
        factorsâ_NN €_NN” including_VBG the_DT cost_NN of_IN a_DT flow_NN cytometer_NN (_( which_WDT ranges_NNS from_IN
        $_$ 30_CD ,_, 000_CD to_TO $_$ 150_CD ,_, 000_CD )_) ,_, technical_JJ and_CC operational_JJ complexity_NN ,_, the_DT need_NN for_IN reliable_JJ
        electricity_NN ,_, and_CC the_DT high_JJ cost_NN of_IN reagentsâ_NN €_NN” have_VBP made_VBN these_DT instruments_NNS
        impractical_JJ and_CC /_NN or_CC difficult_JJ to_TO sustain_VB in_IN resource-scarce_JJ settings_NNS ._. The_DT urgent_JJ need_NN for_IN
        affordable_JJ and_CC technically_RB simple_JJ CD_NNP 4_CD diagnostics_NNS is_VBZ widely_RB recognized_VBN
        [_NN 7_CD â_NN €_NN“ 11_CD ]_NN ._.
        Several_JJ efforts_NNS have_VBP been_VBN made_VBN to_TO develop_VB alternative_NN ,_, affordable_JJ CD_NNP 4_CD counting_VBG methods_NNS
        for_IN resource-poor_JJ settings_NNS ._. Single-purpose_NNP flow_NN cytometers_NNS have_VBP been_VBN designed_VBN solely_RB for_IN
        counting_VBG CD_NNP 4_CD cells_NNS ,_, such_JJ as_IN the_DT Becton_NNP Dickinson_NNP FACSCount_NNP ,_, the_DT Partec_NNP CyFlow_NNP ,_, and_CC desktop_NN
        instruments_NNS from_IN Guava_NNP and_CC PointCare_NNP Technologies_NNPS ._. Although_IN these_DT newer_JJR versions_NNS make_VBP flow_NN
        cytometry_NN more_RBR affordable_JJ in_IN some_DT settings_NNS ,_, reagent_NN costs_NNS remain_VBP high_JJ ,_, and_CC the_DT instruments_NNS
        remain_VBP expensive_JJ and_CC in_IN most_JJS cases_NNS ,_, technically_RB complex_JJ [_NN 7_CD â_NN €_NN“ 13_CD ]_NN ._. Low-cost_NNP
        microbead_NN separation_NN of_IN CD_NNP 4_CD cells_NNS from_IN other_JJ blood_NN cells_NNS ,_, followed_VBN by_IN standard_JJ manual_JJ cell_NN
        counting_VBG techniques_NNS using_VBG a_DT light_JJ microscope_NN ,_, offers_VBZ significantly_RB lower_JJR reagent_NN costs_NNS than_IN
        flow_NN cytometry_NN ._. These_DT methods_NNS ,_, however_RB ,_, are_VBP low_JJ throughput_NN and_CC extremely_RB labor_NN intensive_JJ ,_,
        and_CC appear_VB to_TO be_VB less_RBR accurate_JJ than_IN traditional_JJ flow_NN cytometry_NN ;_: thus_RB ,_, they_PRP have_VBP not_RB been_VBN
        widely_RB adopted_VBN [_NN 13_CD â_NN €_NN“ 18_CD ]_NN ._.
        Less_RBR expensive_JJ CD_NNP 4_CD counting_VBG methods_NNS that_WDT capitalize_VB on_IN low-cost_JJ microfabrication_NN ,_,
        efficient_JJ light_JJ sources_NNS ,_, and_CC affordable_JJ microelectronics_NNS and_CC digital_JJ imaging_NN hardware_NN have_VBP
        been_VBN conceptualized_JJ ,_, but_CC never_RB realized_VBD [_NN 19_CD ,_, 20_CD ]_NN ._. One_CD of_IN us_PRP (_( JTM_NNP )_) has_VBZ previously_RB reported_VBN
        the_DT development_NN of_IN a_DT novel_NN microchip-based_JJ detection_NN system_NN for_IN measuring_VBG analytes_NNS such_JJ as_IN
        acids_NNS ,_, bases_NNS ,_, electrolytes_NNS ,_, and_CC proteins_NNS in_IN solution_NN phase_NN [_NN 21_CD â_NN €_NN“ 23_CD ]_NN ._. This_DT
        electronic_JJ taste_NN chip_NN (_( ETC_NNP )_) system_NN carries_VBZ out_IN chemical_NN and_CC immunological_JJ reactions_NNS on_IN
        microspheres_NNS positioned_VBN in_IN the_DT inverted_JJ pyramidal_NN microchamber_NN wells_NNS of_IN a_DT silicon_NN or_CC
        plastic_NN microchip_NN ,_, which_WDT is_VBZ housed_VBN in_IN a_DT miniature_JJ flow_NN cell_NN ._. Microfluidic_NNP channels_NNS deliver_VBP
        a_DT series_NN of_IN small-volume_JJ reagents_NNS and_CC washes_NNS to_TO the_DT flow_NN cell_NN ,_, and_CC hence_RB to_TO the_DT chip_NN and_CC to_TO
        each_DT one_CD of_IN the_DT microspheres_NNS ._. Optical_NNP signals_NNS generated_VBN by_IN the_DT reactions_NNS on_IN the_DT
        microspheres_NNS are_VBP visualized_JJ and_CC captured_VBN on_IN a_DT charge-coupled_JJ device_NN (_( CCD_NNP )_) with_IN the_DT use_NN of_IN
        transfer_NN optics_NNS and_CC a_DT digital_JJ video_NN chip_NN ._. Using_VBG the_DT ETC_NNP system_NN ,_, complex_JJ immunological_JJ
        assays_NNS ,_, such_JJ as_IN the_DT ones_NNS developed_VBN to_TO quantify_VB cardiac_JJ risk_NN factors_NNS in_IN serum_NN ,_, can_MD be_VB
        performed_VBN with_IN small_JJ sample_NN volumes_NNS ,_, short_JJ analysis_NN times_NNS ,_, and_CC markedly_RB reduced_VBN reagent_NN
        costs_NNS [_NN 22_CD ]_NN ._.
        Further_RB development_NN of_IN the_DT ETC_NNP system_NN has_VBZ shown_VBN that_IN it_PRP could_MD be_VB adapted_VBN to_TO the_DT
        detection_NN of_IN bacteria_NNS ,_, spores_NNS ,_, and_CC living_VBG cells_NNS [_NN 24_CD ]_NN ._. We_PRP hypothesized_VBN that_IN additional_JJ
        modifications_NNS could_MD be_VB made_VBN to_TO provide_VB accurate_JJ ,_, low-cost_JJ CD_NNP 4_CD counts_VBZ to_TO monitor_VB HIV_NNP
        infection_NN in_IN resource-constrained_JJ settings_NNS ._. We_PRP show_VBP that_IN a_DT microchip-based_JJ system_NN can_MD
        perform_VB CD_NNP 4_CD counts_VBZ from_IN 16_CD ._. 5_LS Î_NN¼ l_NN of_IN whole_JJ blood_NN rapidly_RB ,_, simply_RB ,_, and_CC with_IN a_DT high_JJ
        degree_NN of_IN accuracy_NN compared_VBN to_TO flow_VB cytometry_NN ,_, particularly_RB for_IN patients_NNS with_IN CD_NNP 4_CD counts_VBZ
        below_IN 500_CD cells_NNS /_NN Î_NN¼ l_NN ._. We_PRP suggest_VBP how_WRB this_DT prototype_NN system_NN can_MD be_VB readily_RB
        developed_VBN as_IN a_DT low-cost_JJ ,_, portable_JJ device_NN for_IN use_NN in_IN resource-poor_JJ settings_NNS ._.
      
      
        Methods_NNP
        
          Flow_NNP Cell_NNP
          The_DT ETC_NNP system_NN was_VBD originally_RB designed_VBN for_IN microsphere-based_JJ assays_NNS
          [_NN 21_CD â_NN €_NN“ 23_CD ]_NN ._. The_DT modified_VBN version_NN of_IN the_DT flow_NN cell_NN (_( see_VB Figure_NN 1_LS )_) is_VBZ
          enclosed_VBN within_IN a_DT three-piece_JJ metal_NN casing_VBG with_IN a_DT flat_JJ platform_NN permanently_RB affixed_JJ to_TO a_DT
          circular_JJ vertical_JJ support_NN ,_, which_WDT is_VBZ in_IN turn_NN connected_VBN to_TO a_DT screw-on_JJ cap_NN ._. Within_IN the_DT metal_NN
          casing_VBG there_EX are_VBP top_NN and_CC bottom_JJ plastic_NN inserts_NNS made_VBN from_IN PMMA_NNP ._. Fluids_NNP are_VBP introduced_VBN to_TO
          and_CC drained_VBN out_IN of_IN the_DT flow_NN cell_NN through_IN integrated_VBN stainless_JJ steel_NN tubing_VBG within_IN the_DT
          inserts_NNS ._. The_DT bottom_JJ PMMA_NNP insert_VB also_RB features_VBZ a_DT plastic_NN screen_NN disc_NN that_IN acts_NNS as_IN a_DT
          support_NN for_IN a_DT 3_CD -_: Î_NN¼ m_NN Nuclepore_NNP polycarbonate_NN ,_, track-etch_JJ filter_NN (_( Whatman_NNP ,_,
          Florham_NNP Park_NNP ,_, New_NNP Jersey_NNP ,_, United_NNP States_NNPS )_) ,_, which_WDT serves_VBZ as_IN a_DT lymphocyte_NN capture_NN and_CC red_JJ
          blood_NN cell_NN separation_NN membrane_NN ._. A_DT gasket_NN between_IN the_DT membrane_NN and_CC the_DT top_JJ insert_NN prevents_VBZ
          leaks_NNS and_CC ensures_VBZ that_IN the_DT entire_JJ sample_NN is_VBZ delivered_VBN into_IN the_DT flow_NN cell_NN and_CC filtered_VBN
          through_IN the_DT membrane_NN ._. The_DT top_JJ outlet_NN is_VBZ used_VBN with_IN lateral_NN flow_NN for_IN the_DT removal_NN of_IN air_NN
          bubbles_NNS ._.
        
        
          Fluid_NNP Delivery_NN System_NNP
          In_IN initial_JJ studies_NNS ,_, we_PRP used_VBD a_DT single_JJ peristaltic_JJ pump_NN to_TO deliver_VB sample_NN and_CC washes_NNS to_TO
          the_DT flow_NN cell_NN ._. Subsequently_RB ,_, a_DT partially_RB automated_VBN fluid_JJ delivery_NN system_NN was_VBD developed_VBN ._.
          This_DT functional_JJ adaptation_NN uses_VBZ two_CD miniature_JJ OEM_NNP peristaltic_JJ pumps_NNS ,_, each_DT in_IN conjunction_NN
          with_IN a_DT pinch_NN valve_NN ,_, and_CC 0_CD ._. 031_CD -_: in_IN ._. (_( 0_CD ._. 79_CD -_: mm_NN )_) silicone_NN tubing_VBG capable_JJ of_IN delivering_VBG flow_NN
          rates_NNS of_IN 46_CD â_NN €_NN“ 920_CD Î_NN¼ l_NN /_NN min_NN to_TO the_DT flow_NN cell_NN ._. Integrated_NNP
          software_NN (_( LabVIEW_NNP ,_, National_NNP Instruments_NNP ,_, Austin_NNP ,_, Texas_NNP ,_, United_NNP States_NNPS )_) directs_VBZ delivery_NN
          of_IN whole_JJ blood_NN samples_NNS and_CC washes_NNS to_TO the_DT flow_NN cell_NN using_VBG the_DT appropriate_JJ pumps_NNS and_CC
          valves_NNS ._. Sample_NNP filtrate_NN ,_, including_VBG red_JJ blood_NN cells_NNS ,_, is_VBZ captured_VBN in_IN a_DT waste_NN reservoir_NN ._.
        
        
          Optical_NNP Station_NNP and_CC Image_NN Capture_NNP
          The_DT flow_NN cell_NN was_VBD positioned_VBN on_IN the_DT stage_NN of_IN a_DT modified_VBN BX_NNP 2_CD Olympus_NNP (_( Tokyo_NNP ,_, Japan_NNP )_)
          compound_NN microscope_NN equipped_VBN with_IN a_DT 10_CD Ã—_NN objective_NN lens_NN and_CC a_DT high-pressure_JJ
          100_CD W_NNP mercury_NN burner_NN arc_NN lamp_NN as_IN a_DT light_JJ source_NN ._. Focusing_VBG was_VBD maintained_VBN on_IN a_DT fixed_VBN plane_NN
          throughout_IN the_DT duration_NN of_IN the_DT assay_NN ._. Visualization_NNP of_IN AlexaFluor-_NNP 647_CD -_: stained_JJ lymphocytes_NNS
          was_VBD achieved_VBN using_VBG a_DT Cy_NNP 5_CD filter_NN cube_NN (_( 620_CD nm_NN excitation_NN ,_, 660_CD nm_NN long-pass_JJ beam_NN splitter_NN
          dichroic_JJ mirror_VBP ,_, and_CC 700_CD nm_NN emission_NN )_) ,_, while_IN AlexaFluor-_NNP 488_CD -_: stained_JJ lymphocytes_NNS were_VBD
          visualized_JJ with_IN a_DT fluoroisothiocyanate_NN (_( FITC_NNP )_) filter_NN cube_NN (_( 480_CD nm_NN excitation_NN ,_, 505_CD nm_NN
          long-pass_JJ beam_NN splitter_NN dichroic_JJ mirror_VBP ,_, and_CC 535_CD Â_NN ±_NN 25_CD nm_NN emission_NN )_) ._. For_IN each_DT
          study_NN participant_NN ,_, images_NNS were_VBD obtained_VBN from_IN each_DT of_IN five_CD nonoverlapping_VBG regions_NNS of_IN the_DT
          lymphocyte_NN capture_NN membrane_NN in_IN the_DT flow_NN cell_NN ,_, using_VBG a_DT 12_CD -_: bit_NN CCD_NNP digital_JJ camera_NN (_( DVC_NNP ,_,
          Austin_NNP ,_, Texas_NNP ,_, United_NNP States_NNPS )_) mounted_VBD on_IN the_DT microscope_NN ._. Each_DT imaged_JJ region_NN represented_VBD
          0_CD ._. 18_CD Î_NN¼ l_NN of_IN whole_JJ blood_NN ,_, so_IN that_IN for_IN each_DT assay_NN ,_, cells_NNS were_VBD counted_VBN from_IN a_DT
          total_JJ volume_NN of_IN 0_CD ._. 9_CD Î_NN¼ l_NN of_IN blood_NN ._. Each_DT region_NN was_VBD imaged_JJ serially_RB with_IN both_DT
          filter_NN cubes_NNS ._. The_DT corresponding_JJ images_NNS were_VBD stored_VBN separately_RB as_IN monochromatic_JJ eight-bit_JJ
          images_NNS for_IN subsequent_JJ digital_JJ image_NN analysis_NN and_CC automated_VBN cell_NN counting_NN ._.
        
        
          Image_NN Analysis_NNP
          Images_NNP were_VBD analyzed_VBN using_VBG a_DT custom_NN algorithm_NN supported_VBN by_IN Image-_NNP Pro_FW Plus_NNP (_( Media_NNP
          Cybernetics_NNP ,_, Silver_NNP Spring_NNP ,_, Maryland_NNP ,_, United_NNP States_NNPS )_) processing_NN software_NN ._. An_DT iterative_JJ
          approach_NN allowed_VBN for_IN flexible_JJ analysis_NN of_IN data_NNS acquired_VBN under_IN different_JJ conditions_NNS of_IN
          illumination_NN ,_, focus_VB ,_, and_CC sampling_VBG ._. For_IN each_DT iteration_NN ,_, an_DT upper_JJ and_CC lower_JJR value_NN defined_VBD a_DT
          range_NN of_IN green_JJ or_CC red_JJ intensities_NNS that_WDT were_VBD then_RB used_VBN to_TO segment_NN the_DT image_NN ._. Pixels_NNP whose_WP$
          intensity_NN values_NNS fell_VBD within_IN the_DT defined_VBN range_NN were_VBD reassigned_VBN values_NNS of_IN one_CD ,_, while_IN all_DT
          others_NNS were_VBD set_VBN to_TO zero_CD ._. The_DT process_NN yielded_VBD a_DT binary_JJ version_NN of_IN the_DT original_JJ eight-bit_JJ
          image_NN ._. A_DT lymphocyte_NN selection_NN algorithm_NN was_VBD then_RB applied_VBN ._. Objects_NNP (_( i_NNP ._. e_SYM ._. ,_, lymphocytes_NNS )_)
          were_VBD defined_VBN as_IN contiguous_JJ groups_NNS of_IN pixels_NNS with_IN values_NNS of_IN one_CD ._. Object_NNP selection_NN was_VBD
          refined_VBN by_IN a_DT lymphocyte_NN profile_NN (_( defined_VBN by_IN size_NN ,_, aspect_NN ratio_NN ,_, and_CC uniformity_NN )_) ;_: objects_NNS
          not_RB fitting_JJ the_DT profile_NN were_VBD not_RB counted_VBN ._. The_DT number_NN of_IN counted_VBN objects_NNS was_VBD recorded_VBN for_IN
          each_DT iteration_NN ._. From_IN one_CD iteration_NN to_TO the_DT next_JJ ,_, the_DT upper_JJ and_CC lower_JJR intensity_NN limits_NNS used_VBN
          to_TO segment_NN the_DT image_NN were_VBD both_DT increased_VBN by_IN a_DT single_JJ intensity_NN count_NN ._. The_DT final_JJ cell_NN
          count_NN per_IN image_NN was_VBD the_DT maximum_NN object_VBP count_NN over_IN 256_CD iterations_NNS (_( upper_JJ intensity_NN limits_NNS
          1_CD â_NN †_NN’ 255_CD )_) for_IN which_WDT the_DT average_JJ object_VBP roundness_NNS fell_VBN below_IN a_DT threshold_NN
          value_NN ._. In_IN this_DT manner_NN ,_, the_DT software_NN algorithm_NN determined_VBD the_DT optimal_NN analysis_NN parameters_NNS
          for_IN each_DT image_NN individually_RB ,_, greatly_RB relaxing_VBG the_DT stringency_NN of_IN image_NN capture_NN
          requirements_NNS ._. Cell_NNP counts_NNS were_VBD recorded_VBN in_IN a_DT spreadsheet_NN as_IN numbers_NNS of_IN CD_NNP 4_CD
          +_NN CD_NNP 3_CD
          â_NNˆ’ ,_, CD_NNP 4_CD
          +_NN CD_NNP 3_CD
          +_NN ,_, CD_NNP 4_CD
          â_NNˆ’ CD_NNP 3_CD
          +_NN ,_, CD_NNP 8_CD
          +_NN CD_NNP 3_CD
          â_NNˆ’ ,_, CD_NNP 8_CD
          +_NN CD_NNP 3_CD
          +_NN ,_, CD_NNP 8_CD
          â_NNˆ’ CD_NNP 3_CD
          +_NN ,_, and_CC CD_NNP 4_CD
          +_NN CD_NNP 8_CD
          +_NN cells_NNS ,_, depending_VBG on_IN the_DT combination_NN of_IN antibodies_NNS used_VBN ._. Absolute_JJ CD_NNP 4_CD
          counts_NNS were_VBD recorded_VBN as_IN the_DT summed_VBD number_NN of_IN CD_NNP 4_CD
          +_NN CD_NNP 3_CD
          +_NN cells_NNS counted_VBN over_IN five_CD images_NNS ,_, normalized_JJ per_IN microliter_NN of_IN imaged_JJ
          blood_NN ._. CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS were_VBD recoded_JJ as_IN the_DT ratio_NN of_IN CD_NNP 4_CD
          +_NN CD_NNP 3_CD
          +_NN cells_NNS to_TO CD_NNP 8_CD
          +_NN CD_NNP 3_CD
          +_NN cells_NNS counted_VBN over_IN five_CD images_NNS ._. Relative_NNP CD_NNP 4_CD abundance_NN as_IN a_DT
          percentage_NN of_IN total_JJ T_NN lymphocytes_NNS was_VBD recorded_VBN as_IN 100_CD times_NNS the_DT ratio_NN of_IN CD_NNP 4_CD
          +_NN CD_NNP 3_CD
          +_NN cells_NNS to_TO total_VB CD_NNP 3_CD
          +_NN cells_NNS ,_, with_IN cells_NNS counted_VBN over_IN five_CD images_NNS ._.
        
        
          Lymphocyte_NNP Staining_NNP and_CC Delivery_NN
          Antibodies_NNP utilized_JJ in_IN these_DT studies_NNS were_VBD stored_VBN at_IN 4_CD Â_NN °_NN C_NNP and_CC centrifuged_JJ to_TO
          remove_VB precipitated_VBD material_NN prior_RB to_TO use_VB ._. This_DT process_NN ensured_JJ removal_NN of_IN fluorescent_NN
          particulate_NN matter_NN that_WDT could_MD be_VB captured_VBN by_IN the_DT membrane_NN and_CC might_MD interfere_VB with_IN
          imaging_NN ._. For_IN the_DT initial_JJ dilution_NN control_NN studies_NNS ,_, CD_NNP 4_CD cells_NNS were_VBD purified_JJ by_IN
          immunomagnetic_JJ separation_NN from_IN donor_NN buffy_NN coats_NNS ._. CD_NNP 4_CD cells_NNS labeled_VBN with_IN
          AlexaFluor-_NNP 488_CD -_: conjugated_JJ anti-_NN CD_NNP 4_CD antibodies_NNS (_( A_DT 21335_CD ,_, clone_NN
          289_CD â_NN €_NN“ 14120_CD ,_, Molecular_NNP Probes_NNP ,_, Eugene_NNP ,_, Oregon_NNP ,_, United_NNP States_NNPS )_) were_VBD
          introduced_VBN to_TO the_DT flow_NN cell_NN in_IN amounts_NNS ranging_VBG from_IN zero_CD to_TO 200_CD ,_, 000_CD cells_NNS ,_, and_CC washed_VBD
          with_IN phosphate_NN buffered_JJ saline_NN (_( PBS_NNP )_) ._. For_IN whole_JJ blood_NN studies_NNS ,_, 33_CD Î_NN¼ l_NN of_IN whole_JJ
          blood_NN collected_VBN by_IN venipuncture_NN was_VBD incubated_JJ at_IN ambient_NN temperature_NN
          (_( 20_CD â_NN €_NN“ 25_CD Â_NN °_NN C_NNP )_) with_IN 3_CD Î_NN¼ l_NN of_IN AlexaFluor-_NNP 488_CD -_: and_CC
          AlexaFluor-_NNP 647_CD -_: conjugated_JJ antibodies_NNS to_TO CD_NNP 4_CD and_CC CD_NNP 3_CD (_( A_DT 21332_CD ,_, clone_NN
          289_CD â_NN €_NN“ 13801_CD ,_, Molecular_NNP Probes_NNP )_) ,_, respectively_RB ,_, and_CC allowed_VBD to_TO react_VB for_IN 8_CD
          min_NN ._. Similarly_RB ,_, for_IN CD_NNP 8_CD enumeration_NN ,_, 33_CD Î_NN¼ l_NN of_IN whole_JJ blood_NN with_IN 3_CD Î_NN¼ l_NN
          of_IN AlexaFluor-_NNP 488_CD -_: and_CC AlexaFluor-_NNP 647_CD -_: conjugated_JJ antibodies_NNS to_TO CD_NNP 8_CD (_( A_DT 21340_CD ,_, clone_NN
          289_CD â_NN €_NN“ 13804_CD ,_, Molecular_NNP Probes_NNP )_) and_CC CD_NNP 3_CD ,_, respectively_RB ,_, was_VBD allowed_VBN to_TO
          react_VB for_IN 8_CD min_NN at_IN ambient_NN temperature_NN ._. Stained_NNP blood_NN samples_NNS were_VBD brought_VBN up_IN to_TO 1_CD ,_, 000_CD
          Î_NN¼ l_NN with_IN PBS_NNP ,_, half_NN of_IN which_WDT was_VBD introduced_VBN directly_RB into_IN the_DT flow_NN cell_NN
          (_( representing_VBG 16_CD ._. 5_LS Î_NN¼ l_NN of_IN the_DT original_JJ sample_NN of_IN blood_NN )_) and_CC then_RB washed_VBN with_IN 1_CD
          ml_NN of_IN PBS_NNP ._. Because_IN red_JJ blood_NN cells_NNS are_VBP mechanically_RB separated_JJ from_IN white_JJ blood_NN cells_NNS ,_, red_JJ
          blood_NN cell_NN lysis_NNS is_VBZ not_RB necessary_JJ ._. Images_NNP of_IN labeled_VBN cells_NNS captured_VBN on_IN the_DT membrane_NN were_VBD
          obtained_VBN and_CC analyzed_VBN as_IN described_VBN above_IN ._. For_IN SEM_NNP (_( scanning_VBG electron_NN microscopy_NN )_) ,_, a_DT
          fixative_JJ (_( 2_CD %_NN paraformaldehyde_NN /_NN 2_CD ._. 5_LS %_NN glutaraldehyde_NN )_) was_VBD added_VBN into_IN the_DT flow_NN cell_NN and_CC
          rinsed_JJ with_IN PBS_NNP ._. The_DT filter_NN was_VBD removed_VBN from_IN the_DT flow_NN cell_NN ,_, fixed_VBN for_IN 90_CD s_VBZ with_IN OsO_NNP
          4_CD vapor_NN ,_, and_CC then_RB dehydrated_JJ with_IN EtOH_NNP /_NN HMDS_NNP ._. The_DT same_JJ SEM_NNP protocol_NN was_VBD
          applied_VBN to_TO a_DT drop_NN of_IN whole_JJ blood_NN on_IN a_DT glass_NN slide_NN ._.
        
        
          Study_NN Participants_NNS and_CC Comparison_NNP to_TO Flow_NNP Cytometry_NNP
          Blood_NNP was_VBD obtained_VBN from_IN HIV-_NNP 1_CD -_: uninfected_JJ control_NN participants_NNS and_CC HIV-infected_NNP
          participants_NNS at_IN the_DT Massachusetts_NNP General_NNP Hospital_NNP in_IN Boston_NNP ,_, Massachusetts_NNP ,_, United_NNP
          States_NNPS ,_, and_CC from_IN HIV-infected_NNP participants_NNS at_IN the_DT Botswanaâ_NNP €_NN“ Harvard_NNP
          AIDS_NNP Institute_NNP HIV_NNP Reference_NNP Laboratory_NNP in_IN Gaborone_NNP ,_, Botswana_NNP ._. The_DT Botswana_NNP samples_NNS
          originated_VBN from_IN a_DT study_NN of_IN HIV-infected_NNP pregnant_JJ women_NNS attending_VBG
          maternalâ_NN €_NN“ child_NN health_NN clinics_NNS in_IN Gaborone_NNP or_CC three_CD nearby_JJ villages_NNS ,_,
          Molepolole_NNP ,_, Mochudi_NNP ,_, and_CC Lobatse_NNP ._. Six_CD infants_NNS were_VBD also_RB included_VBN in_IN the_DT study_NN ._. Three_CD
          milliliters_NNS of_IN venous_JJ whole_JJ blood_NN was_VBD collected_VBN from_IN each_DT participant_NN (_( in_IN EDTA_NNP
          anticoagulant_NN )_) ._. All_DT samples_NNS were_VBD run_VBN on_IN the_DT microchip_NN on_IN the_DT day_NN of_IN blood_NN collection_NN ._.
          Parallel_JJ samples_NNS were_VBD processed_VBN using_VBG standard_JJ four-color_JJ flow_NN cytometry_NN on_IN a_DT Becton_NNP
          Dickinson_NNP FACSCalibur_NNP ,_, using_VBG the_DT MultiTEST_NNP reagents_NNS and_CC TruCOUNT_NNP beads_NNS ,_, and_CC analyzed_VBD
          using_VBG MultiSET_NNP software_NN ._. All_DT samples_NNS were_VBD processed_VBN by_IN flow_NN cytometry_NN according_VBG to_TO
          standard_JJ operating_NN procedure_NN in_IN the_DT HIV_NNP reference_NN laboratory_NN in_IN Botswana_NNP ._. The_DT majority_NN
          were_VBD processed_VBN within_IN 24_CD h_NN of_IN blood_NN collection_NN ,_, and_CC all_DT were_VBD processed_VBN and_CC analyzed_VBN
          within_IN 72_CD h_NN of_IN blood_NN collection_NN ._. A_DT total_NN of_IN 70_CD participants_NNS were_VBD enrolled_VBN ,_, including_VBG 64_CD
          adults_NNS and_CC six_CD infants_NNS ._. Three_CD adults_NNS did_VBD not_RB have_VB flow_NN cytometry_NN results_NNS available_JJ ,_,
          leaving_VBG 67_CD participants_NNS for_IN analysis_NN ._. The_DT study_NN was_VBD approved_VBN by_IN the_DT institutional_JJ review_NN
          boards_NNS of_IN the_DT participating_VBG institutions_NNS ._. For_IN a_DT preliminary_JJ assessment_NN of_IN assay_NN
          variability_NN ,_, blood_NN from_IN a_DT single_JJ study_NN participant_NN was_VBD assayed_JJ as_IN described_VBN above_IN 20_CD
          separate_JJ times_NNS over_IN the_DT course_NN of_IN a_DT single_JJ afternoon_NN by_IN a_DT single_JJ operator_NN ._.
        
        
          Statistical_NNP Methods_NNP
          The_DT accuracy_NN of_IN the_DT microchip-based_JJ CD_NNP 4_CD counting_VBG system_NN was_VBD determined_VBN by_IN comparing_VBG
          results_NNS directly_RB to_TO parallel_JJ samples_NNS processed_VBN by_IN flow_NN cytometry_NN using_VBG
          Passingâ_NNP €_NN“ Bablok_NNP regression_NN analysis_NN and_CC the_DT
          Blandâ_NNP €_NN“ Altman_NNP methods_NNS comparisons_NNS approach_VBP [_NN 25_CD ,_, 26_CD ]_NN ._. For_IN assay_NN
          reproducibility_NN ,_, a_DT coefficient_NN of_IN variance_NN was_VBD calculated_VBN from_IN 20_CD replicates_NNS of_IN a_DT single_JJ
          participant_NN ._. Data_NNP were_VBD analyzed_VBN and_CC processed_VBN using_VBG Analyse-_NNP It_PRP software_NN (_( Analyse-_NNP It_PRP
          Software_NNP ,_, Leeds_NNP ,_, United_NNP Kingdom_NNP )_) ._.
        
      
      
        Results_NNS
        In_IN initial_JJ experiments_NNS using_VBG the_DT original_JJ ETC_NNP system_NN [_NN 21_CD â_NN €_NN“ 23_CD ]_NN ,_,
        microspheres_NNS were_VBD coated_VBN with_IN monoclonal_NN antibodies_NNS to_TO the_DT lymphocyte_NN surface_NN markers_NNS CD_NNP 3_CD ,_,
        CD_NNP 4_CD ,_, or_CC CD_NNP 8_CD ,_, followed_VBN by_IN microfluidic_JJ delivery_NN of_IN fluorescently_RB labeled_VBN lymphocytes_NNS from_IN
        whole_JJ blood_NN obtained_VBN from_IN non-_NN HIV-infected_NNP participants_NNS ._. Although_IN lymphocytes_NNS were_VBD readily_RB
        captured_VBN ,_, precise_JJ quantification_NN of_IN cell_NN numbers_NNS and_CC CD_NNP 4_CD cell_NN counts_NNS were_VBD not_RB possible_JJ
        using_VBG the_DT microsphere_NN as_IN a_DT surface_NN for_IN lymphocyte_NN capture_NN (_( data_NNS not_RB shown_VBN )_) ._. We_PRP next_RB
        modified_VBN the_DT flow_NN cells_NNS with_IN a_DT disposable_JJ ,_, microporous_JJ membrane_NN filter_NN for_IN lymphocyte_NN
        capture_NN ._. A_DT single_JJ polycarbonate_NN ,_, track-etch_JJ membrane_NN with_IN 3_CD -_: Î_NN¼ m_NN pores_VBZ was_VBD
        immobilized_JJ and_CC secured_VBN within_IN the_DT flow_NN cell_NN ,_, creating_VBG a_DT lymphocyte_NN capture_NN surface_NN with_IN a_DT
        surface_NN area_NN of_IN 80_CD mm_NN
        2_CD ._. Whole_JJ blood_NN samples_NNS were_VBD delivered_VBN to_TO the_DT flow_NN cell_NN from_IN a_DT sample_NN
        reservoir_NN tube_NN ,_, and_CC the_DT membrane_NN within_IN the_DT flow_NN cell_NN was_VBD washed_VBN with_IN PBS_NNP from_IN a_DT second_JJ
        reservoir_NN ._. As_IN in_IN the_DT original_JJ ETC_NNP system_NN ,_, cells_NNS were_VBD imaged_JJ under_IN fluorescence_NN optics_NNS using_VBG
        a_DT mercury_NN arc_NN lamp_NN light_JJ source_NN and_CC a_DT CCD_NNP camera_NN (_( Figure_NN 1_LS )_) ._.
        To_TO confirm_VB that_IN cells_NNS could_MD be_VB adequately_RB captured_VBN ,_, 33_CD Î_NN¼ l_NN of_IN unprocessed_JJ
        whole_JJ blood_NN from_IN non-_NN HIV-infected_NNP participants_NNS was_VBD incubated_JJ for_IN 8_CD min_NN with_IN
        fluorophore-conjugated_JJ anti-_NN CD_NNP 4_CD antibodies_NNS ,_, and_CC delivered_VBN by_IN a_DT peristaltic_JJ pump_NN to_TO the_DT
        modified_VBN microfluidics_NNS chip_NN ._. Red_JJ blood_NN cells_NNS passed_VBN readily_RB through_IN the_DT pores_VBZ under_IN
        appropriate_JJ fluid_JJ flow_NN conditions_NNS ._. In_IN contrast_NN ,_, the_DT majority_NN of_IN white_JJ blood_NN cells_NNS were_VBD
        captured_VBN onto_IN a_DT single_JJ imaging_NN focal_JJ plane_NN (_( Figure_NN 2_LS )_) ._. This_DT mechanical_JJ separation_NN of_IN
        autofluorescent_NN red_JJ blood_NN cells_NNS allows_VBZ for_IN the_DT imaging_NN and_CC counting_NN of_IN white_JJ blood_NN cells_NNS
        from_IN unprocessed_JJ whole_JJ blood_NN without_IN additional_JJ sample_NN processing_NN ,_, such_JJ as_IN centrifugation_NN
        or_CC red_JJ blood_NN cell_NN lysis_NNS ._. Using_VBG the_DT digital_JJ imaging_NN system_NN originally_RB developed_VBD for_IN
        microsphere-based_JJ capture_NN in_IN the_DT ETC_NNP system_NN ,_, fluorescently_RB labeled_VBN white_JJ blood_NN cells_NNS can_MD
        then_RB be_VB imaged_JJ directly_RB on_IN the_DT chip_NN and_CC counted_VBN ._.
        To_TO assess_VB the_DT analytical_JJ validity_NN of_IN the_DT membrane-based_JJ microchip_NN system_NN ,_, we_PRP first_RB
        performed_VBD a_DT dilution_NN control_NN study_NN to_TO evaluate_VB the_DT correlation_NN between_IN total_JJ fluorescence_NN
        intensity_NN and_CC the_DT absolute_JJ number_NN of_IN purified_JJ CD_NNP 4_CD cells_NNS from_IN non-_NN HIV-infected_NNP participants_NNS
        (_( labeled_VBN with_IN fluorophore-conjugated_JJ anti-_NN CD_NNP 4_CD antibody_NN )_) captured_VBN in_IN the_DT microchamber_NN ._. The_DT
        results_NNS show_VBP a_DT linear_JJ correlation_NN between_IN the_DT number_NN of_IN cells_NNS in_IN the_DT sample_NN and_CC the_DT
        intensity_NN of_IN light_JJ emitted_VBN from_IN the_DT membrane_NN filter_NN (_(
        R_NN
        2_CD =_SYM 0_CD ._. 999_CD )_) for_IN a_DT range_NN of_IN CD_NNP 4_CD cell_NN counts_VBZ relevant_JJ to_TO advanced_VBD HIV_NNP
        disease_NN (_( 0_CD â_NN €_NN“ 200_CD CD_NNP 4_CD cells_NNS /_NN Î_NN¼ l_NN blood_NN )_) (_( Figure_NN 3_LS )_) ._. This_DT
        doseâ_NN €_NN“ response_NN study_NN established_VBD proof_NN of_IN the_DT concept_NN that_IN a_DT modified_VBN
        microfluidic_JJ flow_NN cell_NN and_CC a_DT digital_JJ image_NN analysis_NN system_NN can_MD accurately_RB detect_VB and_CC
        measure_VB populations_NNS of_IN whole_JJ blood_NN lymphocytes_NNS labeled_VBN with_IN fluorescent_NN markers_NNS ._.
        We_PRP next_RB quantified_VBN the_DT percentages_NNS of_IN CD_NNP 3_CD ,_, CD_NNP 4_CD ,_, and_CC CD_NNP 8_CD cells_NNS in_IN whole_JJ blood_NN samples_NNS
        from_IN healthy_JJ control_NN participants_NNS using_VBG this_DT system_NN ._. Prior_RB to_TO delivery_NN to_TO the_DT flow_NN cell_NN ,_, we_PRP
        labeled_VBD a_DT 33_CD -_: Î_NN¼ l_NN whole_JJ blood_NN sample_NN with_IN 3_CD Î_NN¼ l_NN of_IN
        fluorophore-conjugated_JJ anti-_NN CD_NNP 3_CD and_CC anti-_NN CD_NNP 4_CD antibodies_NNS for_IN 8_CD min_NN off_IN chip_NN ,_, then_RB diluted_VBD
        the_DT sample_NN with_IN 961_CD Î_NN¼ l_NN of_IN PBS_NNP ,_, and_CC delivered_VBD 500_CD Î_NN¼ l_NN of_IN the_DT resulting_VBG
        sample_NN (_( containing_VBG 16_CD ._. 5_LS Î_NN¼ l_NN of_IN blood_NN )_) to_TO the_DT flow_NN cell_NN using_VBG a_DT fluidics_NNS
        controller_NN ._. Digital_NN images_NNS from_IN one_CD region_NN of_IN the_DT lymphocyte_NN capture_NN membrane_NN were_VBD obtained_VBN
        with_IN two_CD different_JJ emission_NN filters_NNS ,_, one_CD specific_JJ for_IN the_DT AlexaFluor-_NNP 488_CD -_: conjugated_JJ
        antibody_NN used_VBN to_TO stain_VB CD_NNP 4_CD
        +_NN T_NN lymphocytes_NNS green_JJ (_( Figure_NN 4_CD A_DT )_) ,_, and_CC the_DT other_JJ specific_NN for_IN the_DT
        AlexaFluor-_NNP 647_CD -_: conjugated_JJ antibody_NN used_VBN to_TO stain_VB CD_NNP 3_CD
        +_NN T_NN lymphocytes_NNS red_JJ (_( Figure_NN 4_CD B_NNP )_) ._. Automated_NNP digital_JJ merging_VBG of_IN the_DT two_CD
        images_NNS and_CC image_NN processing_NN allowed_VBD the_DT system_NN to_TO distinguish_VB the_DT CD_NNP 3_CD
        +_NN CD_NNP 4_CD
        +_NN T_NN lymphocytes_NNS of_IN interest_NN (_( i_NNP ._. e_SYM ._. ,_, â_NN €_NN œCD_NN 4_CD
        cellsâ_NN €_NN )_) ,_, which_WDT appear_VBP yellow_JJ ,_, from_IN the_DT CD_NNP 4_CD
        +_NN CD_NNP 3_CD
        â_NNˆ’ monocytes_NNS (_( green_JJ )_) and_CC the_DT CD_NNP 3_CD
        +_NN CD_NNP 4_CD
        â_NNˆ’ T_NN lymphocytes_NNS (_( red_JJ )_) (_( Figure_NN 4_CD C_NNP )_) ._.
        We_PRP next_RB developed_VBD a_DT custom_NN algorithm_NN for_IN translating_VBG these_DT digital_JJ images_NNS into_IN accurate_JJ
        CD_NNP 4_CD and_CC CD_NNP 8_CD T_NN cell_NN counts_VBZ using_VBG pixel_NN analysis_NN with_IN the_DT aid_NN of_IN a_DT commercial_JJ image_NN
        processing_NN package_NN ._. Automated_NNP counting_NN of_IN the_DT three_CD subsets_NNS of_IN cells_NNS was_VBD based_VBN on_IN object_VBP
        size_NN ,_, aspect_NN ratio_NN ,_, and_CC uniformity_NN ,_, iterated_JJ across_IN the_DT range_NN of_IN color_NN intensity_NN levels_NNS ._. As_IN
        shown_VBN in_IN Figure_NN 4_CD D_NNP ,_, a_DT binary_JJ mask_NN first_RB removes_VBZ the_DT unwanted_JJ cell_NN types_NNS ,_, and_CC residual_JJ
        objects_NNS representing_VBG CD_NNP 4_CD T_NN cells_NNS are_VBP counted_VBN ._. A_DT similar_JJ protocol_NN was_VBD applied_VBN to_TO a_DT second_JJ
        aliquot_NN of_IN blood_NN stained_JJ with_IN AlexaFluor-_NNP 647_CD -_: conjugated_JJ CD_NNP 3_CD -_: specific_JJ antibody_NN and_CC
        AlexaFluor-_NNP 488_CD -_: conjugated_JJ CD_NNP 8_CD -_: specific_JJ antibody_NN to_TO visualize_VB and_CC count_VB CD_NNP 3_CD
        +_NN CD_NNP 8_CD
        +_NN T_NN lymphocytes_NNS ._.
        In_IN order_NN to_TO calculate_VB an_DT absolute_JJ CD_NNP 4_CD count_NN with_IN standard_JJ flow_NN cytometry_NN ,_, one_CD of_IN two_CD
        measures_NNS must_MD be_VB undertaken_VBN to_TO calculate_VB a_DT concentration_NN in_IN cells_NNS per_IN microliter_NN ._. Either_CC a_DT
        standardized_JJ reference_NN reagent_NN ,_, such_JJ as_IN calibration_NN beads_NNS at_IN a_DT known_VBN concentration_NN ,_, can_MD be_VB
        added_VBN to_TO the_DT assay_NN (_( â_NN €_NN œsingle-platformâ_JJ €_NN flow_NN cytometry_NN )_) ,_, or_CC an_DT
        absolute_JJ total_JJ lymphocyte_NN count_NN in_IN cells_NNS per_IN microliter_NN can_MD be_VB obtained_VBN on_IN a_DT hematology_NN
        analyzer_NN (_( â_NN €_NN œdual-platformâ_JJ €_NN flow_NN cytometry_NN )_) ._. The_DT microchip_NN
        assay_NN we_PRP describe_VBP here_RB uses_VBZ a_DT direct_JJ volumetric_JJ method_NN and_CC functions_NNS as_IN a_DT single-platform_JJ
        approach_NN ._. By_IN delivering_VBG a_DT consistent_JJ volume_NN of_IN blood_NN to_TO the_DT flow_NN chamber_NN (_( 16_CD ._. 5_LS
        Î_NN¼ l_NN of_IN stained_JJ whole_JJ blood_NN ,_, diluted_VBN to_TO a_DT total_JJ volume_NN of_IN 500_CD Î_NN¼ l_NN of_IN
        PBS_NNP )_) ,_, and_CC calculating_VBG the_DT unit_NN volume_NN of_IN blood_NN per_IN digital_JJ image_NN (_( 0_CD ._. 18_CD Î_NN¼ l_NN )_) ,_, we_PRP
        were_VBD able_JJ to_TO count_VB the_DT total_JJ number_NN of_IN CD_NNP 4_CD
        +_NN CD_NNP 3_CD
        +_NN cells_NNS in_IN 0_CD ._. 9_CD Î_NN¼ l_NN of_IN blood_NN ,_, and_CC determine_VB the_DT absolute_JJ CD_NNP 4_CD
        count_NN per_IN microliter_NN ._.
        We_PRP next_RB tested_VBD this_DT rapid_JJ ,_, whole_JJ blood_NN microchip_NN assay_NN in_IN a_DT series_NN of_IN samples_NNS acquired_VBN
        in_IN an_DT HIV_NNP reference_NN laboratory_NN in_IN Botswana_NNP ._. Seventy_CD consecutive_JJ HIV-infected_NNP participants_NNS
        presenting_VBG to_TO the_DT HIV_NNP reference_NN laboratory_NN for_IN standard_JJ CD_NNP 4_CD counting_VBG as_IN part_NN of_IN a_DT vertical_JJ
        transmission_NN study_NN were_VBD enrolled_VBN ,_, of_IN whom_WP 64_CD were_VBD adult_NN women_NNS and_CC six_CD were_VBD infants_NNS ._.
        Parallel_JJ samples_NNS were_VBD processed_VBN by_IN standard_JJ four-color_JJ flow_NN cytometry_NN on_IN a_DT Becton_NNP Dickinson_NNP
        FACSCalibur_NNP ._. The_DT time_NN from_IN blood_NN collection_NN to_TO complete_VB analysis_NN and_CC results_NNS reporting_VBG
        using_VBG the_DT chip-based_JJ assay_NN was_VBD approximately_RB 15_CD min_NN per_IN sample_NN ._. Three_CD adult_NN participants_NNS
        did_VBD not_RB have_VB valid_JJ flow_NN cytometry_NN results_NNS available_JJ ,_, leaving_VBG 61_CD adults_NNS and_CC six_CD infants_NNS for_IN
        analysis_NN ._.
        Representative_NNP processed_VBD data_NNS images_NNS from_IN three_CD participants_NNS ,_, two_CD adult_NN women_NNS and_CC one_CD
        infant_NN ,_, are_VBP shown_VBN in_IN Figure_NN 5_CD ._. Figure_NN 5_CD A_DT shows_VBZ a_DT 31_CD -_: y-old_JJ woman_NN with_IN an_DT absolute_JJ CD_NNP 4_CD count_NN
        by_IN flow_NN cytometry_NN of_IN 83_CD cells_NNS /_NN Î_NN¼ l_NN ._. While_IN numerous_JJ CD_NNP 3_CD
        +_NN T_NN cells_NNS (_( red_JJ )_) are_VBP present_JJ as_IN well_RB as_IN scattered_VBN monocytes_NNS (_( green_JJ )_) ,_, her_PRP$
        low_JJ CD_NNP 4_CD count_NN is_VBZ reflected_VBN in_IN the_DT few_JJ double-labeled_JJ CD_NNP 3_CD
        +_NN CD_NNP 4_CD
        +_NN T_NN cells_NNS (_( yellow_JJ )_) seen_VBN in_IN the_DT image_NN ._. Similar_JJ representative_NN data_NNS images_NNS
        from_IN a_DT young_JJ woman_NN with_IN a_DT CD_NNP 4_CD count_NN of_IN 271_CD cells_NNS /_NN Î_NN¼ l_NN by_IN flow_NN cytometry_NN and_CC a_DT
        5_CD -_: mo-old_JJ infant_NN with_IN a_DT CD_NNP 4_CD percentage_NN of_IN T_NN lymphocytes_NNS of_IN 0_CD ._. 39_CD by_IN flow_NN cytometry_NN are_VBP also_RB
        shown_VBN in_IN Figure_NN 5_CD B_NNP and_CC 5_CD C_NNP ,_, respectively_RB ._. These_DT images_NNS illustrate_VBP the_DT dynamic_JJ range_NN of_IN the_DT
        membrane_NN capture_NN and_CC digital_JJ image_NN analysis_NN system_NN ,_, including_VBG the_DT ability_NN to_TO quantify_VB both_DT
        absolute_JJ CD_NNP 4_CD counts_VBZ and_CC CD_NNP 4_CD percentages_NNS ._.
        We_PRP compared_VBD results_NNS from_IN our_PRP$ microchip_NN assay_NN with_IN results_NNS available_JJ from_IN flow_NN cytometry_NN ,_,
        the_DT latter_JJ obtained_VBN on_IN a_DT FACSCalibur_NNP through_IN standard_JJ clinical_JJ laboratory_NN operating_NN
        procedures_NNS ._. The_DT data_NNS for_IN adult_NN absolute_JJ CD_NNP 4_CD counts_NNS are_VBP plotted_VBD in_IN the_DT
        Blandâ_NNP €_NN“ Altman_NNP methods_NNS comparison_NN plot_NN shown_VBN in_IN Figure_NN 6_CD ._. For_IN 61_CD adult_NN
        participants_NNS with_IN CD_NNP 4_CD counts_VBZ ranging_VBG from_IN 35_CD to_TO 1_CD ,_, 087_CD cells_NNS /_NN Î_NN¼ l_NN (_( mean_VB ,_, 372_CD
        cells_NNS /_NN Î_NN¼ l_NN )_) by_IN flow_NN cytometry_NN ,_, results_NNS show_VBP a_DT good_JJ correlation_NN between_IN absolute_JJ
        CD_NNP 4_CD counts_VBZ measured_VBN by_IN our_PRP$ microchip_NN assay_NN and_CC those_DT measured_VBN by_IN flow_NN cytometry_NN ._.
        Blandâ_NNP €_NN“ Altman_NNP methods_NNS comparison_NN analysis_NN shows_VBZ a_DT bias_NN of_IN
        â_NNˆ’ 50_CD cells_NNS /_NN Î_NN¼ l_NN (_( 95_CD %_NN confidence_NN interval_NN ,_, â_NNˆ’ 81_CD
        to_TO â_NNˆ’ 20_CD cells_NNS /_NN Î_NN¼ l_NN )_) ,_, and_CC good_JJ 95_CD %_NN limits_NNS of_IN agreement_NN (_( Figure_NN 6_CD )_) ._.
        Several_JJ of_IN the_DT results_NNS from_IN participants_NNS at_IN the_DT higher_JJR end_NN of_IN absolute_JJ CD_NNP 4_CD counts_VBZ fall_NN
        outside_IN the_DT 95_CD %_NN limits_NNS ._. For_IN these_DT participants_NNS ,_, individual_JJ lymphocytes_NNS may_MD overlap_VB in_IN the_DT
        digital_JJ images_NNS (_( as_IN seen_VBN in_IN Figure_NN 5_CD C_NNP )_) ,_, which_WDT can_MD interfere_VB with_IN the_DT accuracy_NN of_IN the_DT
        lymphocyte_NN counting_VBG algorithm_NN ._. In_IN resource-limited_JJ settings_NNS ,_, the_DT primary_JJ use_NN of_IN CD_NNP 4_CD counts_VBZ
        is_VBZ as_IN a_DT trigger_NN to_TO initiate_VB antiretroviral_NN therapy_NN ,_, which_WDT typically_RB occurs_VBZ at_IN a_DT CD_NNP 4_CD count_NN
        of_IN 200_CD cells_NNS /_NN Î_NN¼ l_NN ._. Higher_JJR CD_NNP 4_CD count_NN thresholds_NNS of_IN 350_CD and_CC 500_CD cells_NNS /_NN Î_NN¼ l_NN
        are_VBP also_RB used_VBN to_TO increase_VB the_DT intensity_NN of_IN monitoring_VBG ._. For_IN these_DT values_NNS ,_, the_DT sensitivity_NN
        and_CC specificity_NN of_IN our_PRP$ method_NN are_VBP :_: CD_NNP 4_CD <_NN 250_CD ,_, sensitivity_NN =_SYM 0_CD ._. 86_CD ,_, specificity_NN =_SYM 0_CD ._. 81_CD ;_:
        CD_NNP 4_CD <_NN 350_CD ,_, sensitivity_NN =_SYM 0_CD ._. 97_CD ,_, specificity_NN =_SYM 0_CD ._. 83_CD ;_: and_CC CD_NNP 4_CD <_NN 500_CD ,_, sensitivity_NN =_SYM 0_CD ._. 96_CD ,_,
        specificity_NN =_SYM 0_CD ._. 85_CD ._.
        One_CD important_JJ application_NN of_IN our_PRP$ method_NN is_VBZ in_IN pediatric_JJ HIV_NNP monitoring_VBG ._. The_DT wide_JJ range_NN
        of_IN normal_JJ absolute_JJ CD_NNP 4_CD counts_VBZ in_IN infants_NNS and_CC children_NNS requires_VBZ the_DT use_NN of_IN CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS or_CC
        CD_NNP 4_CD percentages_NNS in_IN pediatric_JJ infection_NN ._. Results_NNS for_IN CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS and_CC CD_NNP 4_CD percentages_NNS of_IN T_NN
        lymphocytes_NNS for_IN all_DT 67_CD participants_NNS (_( 61_CD adults_NNS and_CC six_CD infants_NNS )_) are_VBP shown_VBN in_IN Figure_NN 7_CD ._.
        Agreement_NNP ,_, bias_NN ,_, and_CC correlations_NNS between_IN the_DT microchip_NN method_NN and_CC flow_NN cytometry_NN are_VBP
        excellent_JJ for_IN both_DT CD_NNP 4_CD percentages_NNS of_IN T_NN lymphocytes_NNS (_( Figure_NN 7_CD A_DT and_CC 7_CD B_NNP )_) and_CC CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS
        (_( Figure_NN 7_CD C_NNP and_CC 7_CD D_NNP )_) ._. Blandâ_NNP €_NN“ Altman_NNP plots_NNS for_IN both_DT CD_NNP 4_CD percentages_NNS of_IN T_NN
        lymphocytes_NNS and_CC CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS show_VBP low_JJ proportional_JJ bias_NN ,_, with_IN tight_JJ 95_CD %_NN limits_NNS of_IN
        agreement_NN ._. Correlations_NNP are_VBP excellent_JJ for_IN both_DT CD_NNP 4_CD percentages_NNS of_IN T_NN lymphocytes_NNS (_(
        r_LS =_SYM 0_CD ._. 98_CD ,_, 
        p_NN <_NN 0_CD ._. 0001_CD )_) and_CC CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS (_(
        r_LS =_SYM 0_CD ._. 98_CD ,_, 
        p_NN <_NN 0_CD ._. 0001_CD )_) ._. Overall_RB ,_, the_DT data_NNS show_VBP that_IN all_DT three_CD approaches_NNS to_TO
        measuring_VBG CD_NNP 4_CD cell_NN counts_VBZ can_MD be_VB accurately_RB quantified_VBN using_VBG the_DT microchip_NN method_NN ,_, and_CC that_IN
        both_DT adult_NN and_CC pediatric_JJ CD_NNP 4_CD results_NNS can_MD be_VB obtained_VBN ._.
        To_TO determine_VB assay_NN variability_NN ,_, we_PRP examined_VBD 20_CD replicate_VB samples_NNS of_IN blood_NN from_IN a_DT single_JJ
        participant_NN over_IN the_DT course_NN of_IN one_CD day_NN ,_, using_VBG the_DT established_VBN basic_JJ protocol_NN ._. We_PRP determined_VBD
        that_IN the_DT coefficient_NN of_IN variance_NN was_VBD 12_CD %_NN (_( data_NNS not_RB shown_VBN )_) ,_, which_WDT is_VBZ similar_JJ to_TO other_JJ
        methods_NNS of_IN CD_NNP 4_CD counting_VBG [_NN 27_CD ]_NN ._. Although_IN the_DT assay_NN described_VBD here_RB introduced_VBN 16_CD ._. 5_LS
        Î_NN¼ l_NN of_IN blood_NN into_IN the_DT system_NN ,_, the_DT actual_JJ volume_NN of_IN blood_NN analyzed_VBN by_IN digital_JJ
        image_NN analysis_NN is_VBZ only_RB 0_CD ._. 90_CD Î_NN¼ l_NN ._. We_PRP have_VBP conducted_VBN preliminary_JJ studies_NNS that_WDT
        suggest_VBP that_IN we_PRP can_MD accurately_RB measure_VB CD_NNP 4_CD counts_VBZ from_IN less_JJR than_IN 5_CD Î_NN¼ l_NN of_IN blood_NN
        obtained_VBN via_IN fingerstick_NN (_( data_NNS not_RB shown_VBN )_) ;_: additional_JJ studies_NNS will_MD be_VB required_VBN to_TO assess_VB
        the_DT correlation_NN between_IN CD_NNP 4_CD counts_VBZ obtained_VBN by_IN fingerstick_NN and_CC by_IN venipuncture_NN ._.
      
      
        Discussion_NNP
        Our_PRP$ results_NNS provide_VBP proof_NN of_IN principle_NN that_IN low-cost_JJ microfluidic_JJ structures_NNS combined_VBN
        with_IN fluorescence_NN imaging_NN and_CC digital_JJ image_NN analysis_NN can_MD be_VB successfully_RB applied_VBN to_TO the_DT
        measurement_NN of_IN CD_NNP 4_CD cell_NN counts_VBZ ,_, which_WDT are_VBP critical_JJ to_TO the_DT clinical_JJ management_NN of_IN HIV_NNP
        infection_NN ._. The_DT method_NN described_VBD here_RB can_MD deliver_VB both_DT absolute_JJ CD_NNP 4_CD counts_VBZ for_IN adult_NN
        monitoring_NN ,_, and_CC CD_NNP 4_CD percentages_NNS or_CC CD_NNP 4_CD :_: CD_NNP 8_CD ratios_NNS for_IN pediatric_JJ monitoring_NN ._. Most_JJS
        importantly_RB ,_, the_DT rapid_JJ and_CC accurate_JJ CD_NNP 4_CD assessments_NNS obtained_VBN with_IN this_DT method_NN ,_, together_RB
        with_IN its_PRP$ anticipated_VBN low_JJ cost_NN relative_JJ to_TO flow_VB cytometry_NN ,_, may_MD make_VB this_DT type_NN of_IN approach_NN
        ideal_JJ for_IN resource-scarce_JJ settings_NNS ._. As_IN our_PRP$ results_NNS show_NN ,_, this_DT method_NN may_MD be_VB less_RBR accurate_JJ
        at_IN the_DT higher_JJR range_NN of_IN CD_NNP 4_CD counts_VBZ ,_, where_WRB cells_NNS may_MD be_VB more_RBR likely_JJ to_TO overlap_VB in_IN our_PRP$ digital_JJ
        images_NNS ._. While_IN this_DT may_MD limit_VB its_PRP$ applicability_NN ,_, our_PRP$ method_NN is_VBZ accurate_JJ at_IN CD_NNP 4_CD counts_VBZ below_IN
        500_CD cells_NNS /_NN Î_NN¼ l_NN ,_, which_WDT represent_VBP the_DT clinically_RB relevant_JJ CD_NNP 4_CD levels_NNS in_IN
        resource-poor_JJ settings_NNS ._. In_IN addition_NN ,_, both_DT the_DT bias_NN in_IN the_DT method_NN described_VBD here_RB
        (_( â_NNˆ’ 50_CD cells_NNS )_) and_CC the_DT accuracy_NN at_IN higher_JJR CD_NNP 4_CD counts_NNS are_VBP likely_JJ to_TO be_VB
        improved_VBN significantly_RB by_IN the_DT further_JJ development_NN of_IN a_DT disposable_JJ microfluidic_JJ cartridge_NN ,_,
        where_WRB the_DT volume_NN of_IN distribution_NN of_IN the_DT sample_NN will_MD be_VB much_RB smaller_JJR ,_, and_CC more_RBR accurate_JJ
        volumetric_JJ control_NN will_MD be_VB possible_JJ ._.
        Our_PRP$ study_NN was_VBD designed_VBN to_TO evaluate_VB the_DT accuracy_NN of_IN our_PRP$ method_NN against_IN the_DT gold_NN standard_JJ
        in_IN a_DT population_NN of_IN adults_NNS ._. During_IN enrollment_NN ,_, a_DT small_JJ number_NN of_IN pediatric_JJ samples_NNS were_VBD made_VBN
        available_JJ to_TO us_PRP by_IN the_DT staff_NN at_IN Princess_NNP Marina_NNP Hospital_NNP in_IN Botswana_NNP ._. We_PRP chose_VBD to_TO include_VB
        these_DT samples_NNS in_IN the_DT data_NNS presented_VBN here_RB to_TO provide_VB proof_NN of_IN principle_NN that_IN pediatric_JJ CD_NNP 4_CD
        percentages_NNS can_MD also_RB be_VB assessed_VBN with_IN this_DT method_NN ._. Although_IN only_RB six_CD pediatric_JJ samples_NNS were_VBD
        available_JJ ,_, limiting_VBG claims_NNS of_IN statistical_JJ significance_NN ,_, we_PRP believe_VBP the_DT issue_NN of_IN pediatric_JJ
        CD_NNP 4_CD count_NN monitoring_VBG to_TO be_VB of_IN such_JJ importance_NN that_IN the_DT data_NNS merited_JJ inclusion_NN ._. Excluding_VBG
        the_DT six_CD pediatric_JJ samples_NNS does_VBZ not_RB affect_VB the_DT analysis_NN ._.
        The_DT results_NNS presented_VBN here_RB were_VBD obtained_VBN with_IN a_DT stationary_JJ ,_, tabletop_NN monitoring_VBG system_NN
        using_VBG a_DT standard_JJ epifluorescence_NN microscope_NN and_CC commercial_JJ image_NN processing_NN software_NN ._. While_IN
        the_DT methods_NNS we_PRP described_VBD provide_VB the_DT basis_NN for_IN a_DT highly_RB portable_JJ and_CC flexible_JJ miniaturized_VBN
        CD_NNP 4_CD counting_VBG system_NN ,_, it_PRP should_MD be_VB emphasized_VBN that_IN a_DT number_NN of_IN additional_JJ developments_NNS are_VBP
        required_VBN to_TO enable_VB the_DT widespread_JJ use_NN of_IN this_DT approach_NN in_IN resource-limited_JJ settings_NNS ._. With_IN
        additional_JJ engineering_NN of_IN optics_NNS ,_, electronics_NNS ,_, and_CC mechanical_JJ components_NNS along_IN with_IN
        advancements_NNS in_IN integrated_VBN microfluidic_JJ systems_NNS ,_, it_PRP should_MD be_VB possible_JJ to_TO develop_VB a_DT
        point-of-care_JJ instrument_NN that_WDT is_VBZ battery-powered_JJ ,_, uses_VBZ simple_JJ light_JJ emitting_VBG diodes_NNS (_( LEDs_NNP )_) ,_,
        and_CC secures_NNS analyzable_JJ digital_JJ images_NNS with_IN affordable_JJ video_NN imaging_NN chips_NNS ._. When_WRB combined_VBN
        with_IN an_DT embedded_VBN microprocessor_NN and_CC disposable_JJ assay_NN cartridges_NNS for_IN both_DT adult_NN and_CC
        pediatric_JJ monitoring_NN manufactured_VBN from_IN injection-molded_JJ plastic_NN ,_, it_PRP should_MD be_VB possible_JJ to_TO
        create_VB a_DT functional_JJ CD_NNP 4_CD counting_VBG device_NN that_WDT can_MD be_VB used_VBN at_IN the_DT point_NN of_IN care_NN ._. Further_RB
        trials_NNS in_IN a_DT larger_JJR ,_, more_RBR diverse_JJ cohort_NN of_IN patients_NNS ,_, including_VBG adult_NN men_NNS and_CC children_NNS ,_, will_MD
        be_VB necessary_JJ to_TO confirm_VB the_DT accuracy_NN of_IN the_DT method_NN ,_, including_VBG an_DT assessment_NN of_IN assay_NN bias_NN
        and_CC reproducibility_NN ._. Such_JJ a_DT device_NN is_VBZ currently_RB in_IN commercial_JJ development_NN ,_, and_CC may_MD be_VB
        available_JJ by_IN early_JJ 2006_CD ._. While_IN it_PRP is_VBZ too_RB early_JJ to_TO provide_VB an_DT accurate_JJ cost_NN estimate_NN for_IN a_DT
        portable_JJ instrument_NN and_CC disposable_JJ plastic_NN CD_NNP 4_CD assay_NN ,_, we_PRP expect_VBP the_DT equipment_NN cost_NN would_MD be_VB
        substantially_RB lower_JJR than_IN for_IN flow_NN cytometry_NN ,_, and_CC the_DT assay_NN cost_NN would_MD be_VB similar_JJ to_TO assays_NNS
        using_VBG existing_VBG methods_NNS (_( Table_NNP 1_LS )_) ._.
        Although_IN several_JJ CD_NNP 4_CD counting_VBG systems_NNS are_VBP now_RB used_VBN in_IN resource-limited_JJ settings_NNS ,_, they_PRP
        remain_VBP suboptimal_NN to_TO meet_VB the_DT needs_NNS of_IN HIV_NNP care_NN and_CC treatment_NN scale-up_JJ ._. None_NN can_MD truly_RB be_VB
        used_VBN at_IN the_DT point_NN of_IN care_NN beyond_IN a_DT district_NN hospital_NN or_CC similar_JJ facility_NN ,_, and_CC either_CC the_DT
        capital_NN and_CC operating_NN costs_NNS remain_VBP high_JJ ,_, or_CC throughput_NN is_VBZ low_JJ ,_, or_CC both_DT (_( Table_NNP 1_LS )_) ._. Pediatric_NNP
        monitoring_VBG using_VBG CD_NNP 4_CD percentages_NNS also_RB remains_VBZ largely_RB unavailable_JJ ._. The_DT method_NN we_PRP describe_VBP
        here_RB addresses_NNS several_JJ of_IN the_DT limitations_NNS of_IN performing_VBG diagnostic_JJ assays_NNS in_IN
        resource-limited_JJ settings_NNS ._. First_LS ,_, sample_NN volumes_NNS are_VBP minimal_JJ ,_, so_IN that_IN tests_NNS can_MD be_VB
        performed_VBN on_IN fingerstick_NN samples_NNS of_IN blood_NN ,_, circumventing_VBG the_DT need_NN for_IN venipuncture_NN ,_, and_CC
        minimizing_VBG both_DT medical_JJ waste_NN and_CC operator_NN exposure_NN to_TO biohazardous_JJ material_NN ._. Second_JJ ,_,
        reagent_NN use_NN is_VBZ minimized_VBN in_IN the_DT microchip_NN system_NN ,_, reducing_VBG reagent_NN costs_NNS by_IN as_RB much_JJ as_IN 90_CD %_NN ._.
        Third_NNP ,_, labor-_NN and_CC equipment-intensive_JJ sample_NN preparation_NN is_VBZ eliminated_VBN ._. Fourth_JJ ,_, the_DT
        microchip_NN CD_NNP 4_CD assay_NN is_VBZ extremely_RB rapid_JJ ._. CD_NNP 4_CD results_NNS in_IN the_DT prototype_NN system_NN described_VBD here_RB
        are_VBP available_JJ in_IN less_JJR than_IN 15_CD min_NN from_IN the_DT time_NN of_IN blood_NN collection_NN ._. In_IN a_DT mature_VBP
        microfluidic_JJ device_NN with_IN push-button_JJ operation_NN ,_, results_NNS should_MD be_VB available_JJ in_IN less_JJR than_IN 10_CD
        min_NN ,_, and_CC thus_RB can_MD be_VB used_VBN to_TO make_VB real-time_JJ clinical_JJ decisions_NNS at_IN the_DT point_NN of_IN care_NN ._. Fifth_NNP ,_,
        the_DT assay_NN is_VBZ technically_RB simple_JJ ,_, analogous_JJ to_TO a_DT portable_JJ glucometer_NN ,_, and_CC ultimately_RB will_MD be_VB
        useable_JJ by_IN a_DT health-care_NN worker_NN in_IN remote_JJ settings_NNS with_IN minimal_JJ training_NN ,_, extending_VBG the_DT
        reach_NN of_IN CD_NNP 4_CD assays_NNS to_TO district_NN hospitals_NNS and_CC remote_JJ clinics_NNS ,_, and_CC reducing_VBG labor_NN costs_NNS ._.
        Sixth_NNP ,_, both_DT adult_NN and_CC pediatric_JJ monitoring_NN are_VBP possible_JJ ._.
        We_PRP believe_VBP that_IN the_DT future_NN of_IN low-cost_JJ diagnostics_NNS for_IN use_NN in_IN the_DT developing_VBG world_NN lies_VBZ
        in_IN the_DT development_NN of_IN new_JJ lab-on-a-chip_JJ technologies_NNS that_WDT integrate_VB sample_NN preparation_NN and_CC
        sample_NN measurement_NN systems_NNS into_IN miniaturized_VBN devices_NNS with_IN minimal_JJ power_NN requirements_NNS ._.
        Preliminary_JJ cost_NN estimates_NNS for_IN the_DT instrumentation_NN here_RB described_VBD suggest_VBP ,_, at_IN a_DT minimum_NN ,_, a_DT
        10_CD -_: fold_VB reduction_NN in_IN the_DT cost_NN for_IN the_DT associated_VBN measurement_NN system_NN ._. Further_RB ,_, reagent_NN
        consumption_NN for_IN the_DT microchip_NN system_NN can_MD be_VB reduced_VBN by_IN a_DT similar_JJ factor_NN relative_JJ to_TO flow_VB
        cytometry_NN ,_, while_IN sample_NN storage_NN and_CC shipping_VBG costs_NNS are_VBP expected_VBN to_TO be_VB reduced_VBN dramatically_RB
        by_IN virtue_NN of_IN the_DT point-of-care_JJ capabilities_NNS of_IN this_DT new_JJ lab-on-a-chip_JJ structure_NN ._. The_DT
        importance_NN of_IN microtechnologies_NNS to_TO the_DT realities_NNS of_IN laboratory_NN infrastructure_NN worldwide_NN has_VBZ
        been_VBN recognized_VBN previously_RB [_NN 28_CD â_NN €_NN“ 30_CD ]_NN ._. Although_IN CD_NNP 4_CD counting_VBG represents_VBZ the_DT
        most_RBS urgent_JJ need_NN in_IN HIV_NNP diagnostics_NNS for_IN resource-poor_JJ settings_NNS ,_, the_DT microchip_NN platform_NN is_VBZ
        adaptable_JJ to_TO other_JJ important_JJ assays_NNS ._. Through_IN the_DT interface_NN of_IN the_DT lymphocyte_NN capture_NN
        membrane_NN described_VBD here_RB with_IN the_DT previously_RB reported_VBN microchip_NN arrays_NNS ,_, cellular_JJ assays_NNS like_IN
        CD_NNP 4_CD counts_VBZ can_MD be_VB multiplexed_JJ with_IN other_JJ molecular_JJ biomarker_NN measurements_NNS (_( i_NNP ._. e_SYM ._. ,_, proteins_NNS
        and_CC nucleic_JJ acids_NNS )_) on_IN a_DT single_JJ miniaturized_VBN chip_NN ._. The_DT rapid_JJ extension_NN of_IN the_DT chip-based_JJ CD_NNP 4_CD
        counting_VBG method_NN described_VBD here_RB to_TO HIV_NNP RNA_NNP measurements_NNS ,_, diagnostics_NNS for_IN opportunistic_JJ
        infections_NNS ,_, liver_NN enzymes_NNS ,_, and_CC other_JJ biochemical_JJ markers_NNS of_IN interest_NN in_IN infectious_JJ disease_NN
        is_VBZ feasible_JJ ._.
      
    
  
